Lung cancer Posts on Medivizor
Navigation Menu

Lung cancer Posts on Medivizor

What are the long-term effects of treatment with a biological drug versus chemotherapy for patients with advanced non-small cell lung carcinoma?

Posted by on Mar 29, 2020 in Lung cancer | 0 comments

In a nutshell This study compared the long-term effects of biological drug pembrolizumab (Keytruda) with chemotherapy drug docetaxel (Taxotere) in patients with advanced non-small cell lung carcinoma (NSCLC). The study found that pembrolizumab increased survival and had fewer side effects than docetaxel. Some background Patients with advanced...

Read More

Side effects of immunotherapy vs chemotherapy for the treatment of lung cancer

Posted by on Feb 29, 2020 in Lung cancer | 0 comments

In a nutshell This study wanted to compare the side effects of immunotherapy and those of chemotherapy for lung cancer. The study found that immunotherapy was associated with fewer side effects than treatment with chemotherapy. Some background Standard treatment for cancer included chemotherapies. These include drugs that attack and kill cancer cells....

Read More

Treating advanced and reoccurring small cell lung cancer with pembrolizumab

Posted by on Jan 26, 2020 in Lung cancer | 0 comments

In a nutshell This study wanted to find out if pembrolizumab (Keytruda) treatment works in patients with small-cell lung cancer who have received at least two other types of cancer treatment before. The study found that treatment with pembrolizumab was effective and well tolerated in these patients. Some background Small-cell lung cancer (SCLC)...

Read More

Durvalumab after chemoradiotherapy for non-small cell lung cancer: analysis from the patients’ perspective

Posted by on Dec 23, 2019 in Lung cancer | 0 comments

In a nutshell This study evaluated the patient-reported outcomes after treatment with durvalumab (Imfinzi) for stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed. This study concluded that durvalumab did not affect the quality of life of these patients. Some background NSCLC is the most common form of lung cancer...

Read More

Adding ramucirumab to erlotinib treatment for patients with advanced non-small cell lung cancer with EGFR mutations

Posted by on Dec 20, 2019 in Lung cancer | 0 comments

In a nutshell This study wanted to find out if using two kinds of medication together worked better than only one medication to treat advanced non-small cell lung cancer that has not been treated before. The study found that using ramucirumab (Cyramza) with erlotinib (Tarceva) was better than using erlotinib alone. Some background There are a number...

Read More

My Oncologist Doesn’t Believe Food Is Necessary

My Oncologist Doesn’t Believe Food Is Necessary

Posted by on Dec 3, 2019 in Blog, Breast cancer, Colorectal cancer, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 3 comments

By Steve Gillman What my cancer taught me about medical “evidence” and how much is enough I exaggerate. My oncologist probably does believe humans need food, but I suspect the belief makes him uncomfortable, since no double-blind studies have been done to prove it. Like many doctors, his general approach to treatment is that if something hasn’t been...

Read More

Evaluating immune-related side effects associated with pembrolizumab.

Posted by on Nov 29, 2019 in Lung cancer | 0 comments

In a nutshell This study wanted to find out what put patients at risk of having immune-related side effects when they were treated with pembrolizumab (Keytruda). The study found that patients with a higher body mass index (BMI; a measurement of weight in relation to height) and more cycles of treatment were more likely to determine immune-related side...

Read More

Can bisphosphonates improve treatment outcomes for patients with lung cancer spread to the bones?

Posted by on Nov 3, 2019 in Lung cancer | 0 comments

In a nutshell This study evaluated whether zoledronate (Zometa) combined with TKI therapy is more effective than TKI therapy alone for patients with non-small cell lung cancer (NSCLC) spread to the bones. This study concluded that adding zoledronate to TKI therapy improved survival outcomes for these patients. Some background NSCLC is the most common...

Read More